NASDAQ:XFOR X4 Pharmaceuticals Q4 2025 Earnings Results & Report $3.04 +0.21 (+7.24%) As of 02:33 PM Eastern This is a fair market value price provided by Massive. Learn more. X4 Pharmaceuticals beat analyst expectations on both earnings and revenue in its Q4 2025 results, released March 17, 2026. The company reported EPS of -$0.22 versus the -$0.36 consensus estimate, while revenue of $2.57 million topped the $1.68 million estimate by $891 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 17, 2026TimeBefore Market OpensConference Call7:00 AM ET X4 Pharmaceuticals EPS ResultsActual EPS-$0.22Consensus EPS -$0.36Beat/MissBeat by +$0.14One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersX4 Pharmaceuticals Revenue ResultsActual Revenue$2.57 millionExpected Revenue$1.68 millionBeat/MissBeat by +$891.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) X4 Pharmaceuticals Q4 2025 Earnings FAQ Did X4 Pharmaceuticals beat earnings estimates for Q4 2025? X4 Pharmaceuticals (NASDAQ:XFOR) reported earnings of -$0.22 per share for Q4 2025, beating the consensus estimate of -$0.36. The report was announced on Tuesday, March 17, 2026. What was X4 Pharmaceuticals' revenue for Q4 2025? X4 Pharmaceuticals reported revenue of $2.57 million for Q4 2025, against a consensus estimate of $1.68 million. X4 Pharmaceuticals Earnings HeadlinesBrookline Capital Markets Comments on XFOR FY2030 EarningsNovember 9, 2026 | americanbankingnews.comX4 Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 5, 2026 | marketscreener.comMToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.November 17 at 1:00 AM | Behind the Markets (Ad)X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNovember 4, 2026 | globenewswire.comX4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026November 3, 2026 | globenewswire.comX4 Pharmaceuticals, Inc. (XFOR) Analyst/Investor Day TranscriptOctober 30, 2026 | seekingalpha.comSee More X4 Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like X4 Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on X4 Pharmaceuticals and other key companies, straight to your email. Email Address About X4 PharmaceuticalsX4 Pharmaceuticals (NASDAQ:XFOR) is a biopharmaceutical company focused on developing treatments for rare diseases involving dysfunction of the CXCR4 receptor, which plays a role in the movement of immune cells in the body. Its lead medicine, mavorixafor, is marketed in the United States as Xolremdi. The U.S. Food and Drug Administration approved it in 2024 for people aged 12 and older with WHIM syndrome, a rare inherited condition that can leave patients vulnerable to infections. X4 has also studied mavorixafor for other conditions associated with low levels of certain blood cells, including chronic neutropenia. The company’s work has centered on therapies that target CXCR4 to help improve immune-cell circulation.View X4 Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.